.png)
The
National Institute of Allergy and Infectious Diseases (NIAID), part of
the National Institutes of Health has awarded SRI International a new
$49 million, seven-year contract, to carry on preclinical development of
probable therapies for HIV infection and AIDS. The contract award assists the
development of medicines to treat HIV and AIDS and the complexities and
opportunistic infections related with the disease, as well as
microbicides for avoiding sexual transmission of HIV.
More than 35 million people are infected
with HIV across globe, according to the World Health Organization.
Although considerable advances in therapeutics to treat HIV and AIDS,
more effective and less toxic drugs and preventive treatments, such as
microbicides, to prevent the sexual and perinatal transmission of HIV
are still required.Read complete story at http://www.tendersontime.com/blog-detail/sri-international-receives-49-million-contact-study-new-therapies-hiv-and-aids-205.php
No comments:
Post a Comment